Company Filing History:
Years Active: 2015
Title: Innovations of Rahul Sharma in Bioconjugation Technology
Introduction
Rahul Sharma is an innovative inventor based in Baton Rouge, LA (US). He has made significant contributions to the field of bioconjugation, particularly in the development of calcium phosphosilicate nanoparticles for targeted drug delivery. His work focuses on enhancing the efficacy of chemotherapy and imaging agents while minimizing systemic exposure.
Latest Patents
Rahul Sharma holds a patent for his invention titled "Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo." This patent describes non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) that are bioconjugated to targeting molecules specific to certain cells. The CPNPs remain stable at normal physiological pH, allowing for the compartmentalization of chemotherapy and imaging agents within the nanoparticles. Once taken up by the target cells, the CPNPs dissolve at intracellular pH, releasing the agents precisely where they are needed. This innovative approach not only limits systemic exposure but also delivers a higher concentration of therapeutic agents directly to the affected cells.
Career Highlights
Rahul Sharma is associated with the Penn State Research Foundation, where he continues to advance his research in bioconjugation technology. His work has the potential to revolutionize cancer treatment by providing targeted therapies that improve patient outcomes.
Collaborations
Some of his notable coworkers include Thomas T Morgan and Brian M Barth, who contribute to the collaborative efforts in research and development within the foundation.
Conclusion
Rahul Sharma's innovative work in bioconjugation technology exemplifies the potential of targeted therapies in medicine. His contributions are paving the way for more effective treatments in oncology and beyond.